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ABSTRACT
U1 interference (U1i) is a novel method to block gene
expression. U1i requires expression of a 5’-end-
mutated U1 snRNA designed to base pair to the
3’-terminal exon of the target gene’s pre-mRNA that
leads to inhibition of polyadenylation. Here, we show
U1i is robust (
T 95%) and a 10-nt target length is
sufficient for good silencing. Surprisingly, longer
U1 snRNAs, which could increase annealing to the
target, fail to improve silencing. Extensive mutagen-
esis of the 10-bp U1 snRNA:target duplex shows
that any single mismatch different from GU at posi-
tions 3–8, destroys silencing. However, mismatches
within the other positions give partial silencing,
suggesting that off-target inhibition could occur.
The specificity of U1i may be enhanced, however, by
the fact that silencing is impaired by RNA secondary
structure or by splicing factors binding nearby, the
latter mediated by Arginine-Serine (RS) domains. U1i
inhibition can be reconstituted in vivo by tethering of
RS domains of U1-70K and U2AF65. These results
help to: (i) define good target sites for U1i; (ii) identify
and understand natural cellular examples of U1i;
(iii) clarify the contribution of hydrogen bonding to
U1i and to U1 snRNP binding to 5’ splice sites and
(iv) understand the mechanism of U1i.
INTRODUCTION
Technologies to silence speciﬁc vertebrate genes have
rapidly developed for studying the function of individual
genes and hold great promise as molecular therapies.
The leading technology is RNA interference (RNAi),
which can inhibit gene expression 5- to 20-fold. U1i
(U1 small nuclear RNA–U1 snRNA- interference) is a
relatively new addition to the gene silencing tool kit that
gives impressively high levels (up to 1000-fold) of silencing
of reporter genes (1–3) and high levels (20-fold) of
endogenous genes (2,3). U1i has recently been shown to
have eﬃcacy against HIV replication (4) and also works
in animal models (Abad,X. and Puri,F., unpublished data)
and thus holds great promise for knockdown studies and
gene therapy applications. U1i is based on the ﬁnding that
a U1 snRNP bound to the 30-end of a pre-mRNA can
inhibit pre-mRNA 30-end processing and therefore the
gene’s expression. The processing of pre-mRNA to become
mature mRNA is an obligatory step in the expression of
eukaryoticprotein-encodinggenes(5).Nearlyall metazoan
pre-mRNAs undergo 50 end capping, splicing to remove
introns and join exons, and 30 end processing, where the
poly(A) tail is added by a cleavage and polyadenylation
reaction that requires a poly(A) signal A(A/U)UAAA and
a downstream GU-rich sequence that ﬂanks the poly(A)
site. The mature mRNA is then exported to the cytoplasm
where it can be translated.
The U1 small nuclear ribonucleoprotein (U1 snRNP) is
a constitutive splicing factor and, for certain viral genes,
can regulate 30-end processing. In humans, U1 snRNP is
comprised of the 164-nt long U1 snRNA bound by 10
proteins: seven Sm proteins and three U1 snRNP-speciﬁc
proteins U1A, U1C and U1-70K (Supplementary data
Figure S1). U1 snRNP functions in pre-mRNA splicing by
choosing the donor exon–intron boundary via a base
pairing interaction between nts 2–11 of U1 snRNA and
the 50 splice site sequence (ss) (6). The most deﬁnitive
experiment to show this interaction involved expression
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activity to a mutated 50ss only when nts 2–11 of the U1
snRNA were complementary to the mutated 50ss (7–11).
Of the  300000 human natural 50ss sequences most have
a modest complementarity with U1 snRNA with the mean
being 6/10nt. Thus, many factors have been described that
regulate U1 snRNP binding to the 50ss (12), such as the
nuclear cap binding complex (CBC), T-cell intracellular
antigen 1 (TIA-1) or SR proteins that bind splicing
enhancers or silencers. CBC binds the nuclear cap at the
50end of the pre-mRNA and increases the binding of U1
snRNP to the ﬁrst 50ss (13). TIA-1, a factor linked to
translation control binds the RNA downstream of some
50ss sequences and increases U1 snRNP binding to a weak
50ss by direct interaction with U1C (14,15). SR proteins
bind sequences close to the 50ss and aﬀect U1 snRNP
binding by interaction with U1-70K leading to exon
skipping or inclusion (16,17).
Aside from this well-studied splicing function, U1
snRNP can also act as a potent inhibitor of gene
expression by inhibiting pre-mRNA 30 end formation.
The expression of late genes of certain papillomaviruses
was the ﬁrst identiﬁed natural occurring example of this
inhibitory activity of U1 snRNP (2). Inhibition requires
U1 snRNP to base pair to a target 50ss-like sequence
located in the 30 terminal exon of the papillomavirus
mRNA. We call such 30-terminal exon sequences U1-
binding sites so as to distinguish them from 50ss sequences
as they are functionally diﬀerent. The same U1 snRNA nts
2–11 that are used in 50ss recognition are also used to base
pair to the papillomavirus U1-binding site. Subsequent to
its discovery in papillomaviruses, a number of studies
established key aspects of the inhibitory mechanism. After
U1 snRNP binding to the U1-binding site, the U1-70K
component of the U1 snRNP directly binds to and inhibits
the polyadenylation activity of nuclear poly(A) polymer-
ase, the enzyme that catalyzes addition of the poly(A)
tail (18). This was shown both in vitro and in vivo as
exogenous U1 snRNAs that lack the U1-70K binding site
fail to inhibit polyadenylation (1,4). Thus, inhibited pre-
mRNA is cleaved at the 30-end but it is not polyadeny-
lated. Without a poly(A) tail, the pre-mRNA fails to
mature and is rapidly degraded in the nucleus leading to
reduced levels of that gene’s mRNA. Up to very recent,
natural U1-binding sites had only been found in
papillomaviruses. However, we recently identiﬁed the
ﬁrst example of a mammalian gene having a natural U1-
binding site in the 30 terminal exon (45). Although this
site matches the consensus sequence, and so should be
constitutively active, its activity is inﬂuenced by two types
of ﬂanking sequences, one that represses via an RNA
secondary structure and the other that stimulates via
binding a trans-acting factor. Thus, the inhibitory activity
of strong U1-binding sites can be readily regulated and so
represent an additional mechanism for the cell to regulate
the biosynthesis and activity of mRNA.
This inhibitory activity of U1 snRNP forms the basis of
the U1i silencing technology, which is designed to mimic
what has been described in papillomavirus. Expression of
an exogenous U1 snRNA, whose 50-end has been modiﬁed
to base pair with a target mRNA sequence, inhibits target
mRNA expression by inhibiting polyadenylation (1,3,19).
The speciﬁcity of inhibition is underscored by the fact that
U1i does not aﬀect expression of certain histone mRNAs
that lack a poly(A) tail. The 30-end processing of most
of the replication-dependent histone mRNAs utilize a
specialized stem–loop signal to produce a mature mRNA
30 end (20). The inhibitory mechanism of U1i is speciﬁc to
the poly(A) signal as inhibition was lost when the target
gene’s poly(A) signal was replaced by such a histone 30 end
formation signal (3). The inhibitory aﬀect of U1 snRNP
on poly(A) polymerase would lead one to expect that an
optimal target sequence should be close to the site of
poly(A) tail addition. Surprisingly, this is not the case as
strong inhibition was seen even when the target site was
moved far (up to 1190nt) upstream of the poly(A) signal.
However, inhibition was lost when the U1 target site was
placed upstream of an intron (3). This and other reports
led to the realization that the U1 target site needs to be
in the 30-terminal exon to inhibit polyadenylation.
This makes the U1i system distinct from traditional
inhibitory antisense technologies or RNAi where the
target site can be in any part of the mRNA and the
mechanism involves degradation of mature cytoplasmic
mRNA or translation inhibition (21–23).
The rules that govern U1i were ﬁrst studied in reporter
genes where inhibition is conferred by insertion into the
terminal exon of a consensus U1 target site that binds
endogenous U1 snRNA (1–3). Insertion of a single U1
target site typically gave high inhibitory activities in the
range of 15- to 30-fold and insertion of two or more U1
target sites gave synergistic, enhanced inhibitory activity
up to 1000-fold. Such high inhibitory levels are unprece-
dented. The application of U1i to silence endogenous
genes requires expression of a 50-end-mutated U1 snRNA
and typically gives 10- to 20-fold inhibitory levels.
Expression of multiple 50-end mutated U1 snRNAs that
target diﬀerent parts of the terminal exon of the same gene
also gives synergistic enhanced inhibition. Also, inhibition
works in both transiently and stably transfected cells.
In spite of the great potential of U1i, the success of this
technique has been hampered by the paucity of informa-
tion regarding the nature of the target sites and the
modiﬁcations that can be done to the U1 snRNA that
result in good inhibitory molecules. In this work, we study
the eﬀect on silencing eﬃciency of varying the length
of the U1 snRNA:target site duplex and the presence of
mismatches in the duplex. We also analyze the eﬀect of
inhibition when the target site is either close to or partially
within structured regions of the mRNA or is near
sequences bound by factors involved in constitutive or
alternative splicing. Finally, we dissect the partners
involved in U1i. Removal of U1-70K protein results in
an inactive U1i complex, which can be reactivated by
tethering to the complex RS domain of U1-70K or of the
splicing factor U2AF65. These results provide a new
insight into the mechanism by which U1i works, guide the
design of good U1i inhibitory molecules and are
important for predicting naturally occurring U1-binding
sites and the factors that regulate them. Also, our results
may help to understand U1 snRNA binding to the
pre-mRNA during splicing as they serve to highlight the
Nucleic Acids Research, 2008, Vol. 36, No. 7 2339importance of hydrogen bonding to allow 50ss recognition
by U1 snRNP.
MATERIALS AND METHODS
Cell linesand transfections
HeLa cells were obtained from the ATCC and cultured in
DMEM medium, supplemented with 10% FBS and 1%
penicillin–streptomycin at 378C in a 5% CO2 atmosphere.
All cell culture reagents were obtained from Invitrogen.
Plasmids were transfected using calcium phosphate as
described (24) or Polyfect (Qiagen) as per manufacturer’s
instructions.
Plasmids
Either pGL2 or pGL3-Promoter plasmids (Promega) were
used as a ﬁreﬂy luciferase transfection control. All the
Renilla luciferase expressing plasmids used in this work
were derived from pRL-SV40 (Promega). The pRL/
87wtU1 and pRL/145wtU1 have already been described
and were previously called pSV/87WT and pSV/145WT,
respectively (3). The Renilla plasmids in Figures 1, 2, 5
and 6 with U1-binding site insertions were made by
ligation of double-stranded oligonucleotides (Sigma) into
the XbaI–NotI site of pRL-SV40 (Promega). The Renilla
plasmids in Figures 3 and 4 with U1-binding site insertions
were derived from pL3 (3) that had an Adenovirus
L3-derived 30UTR and poly(A) signal sequences in place
of the SV40 30UTR and poly(A) signal sequences. The
Renilla plasmid with two MS2 binding sites in Figure 7D
and E are as previously described (46). MS2 plasmids
express MS2 or MS2 fused to the RS domain of ASF/SF2
(MS2/ASF/SF2), U2AF65 (MS2/U2AF65), U1-70K
(MS2/70K) or the mutated RS domain of ASF/SF2
(MS2/mutASF/SF2) or U2AF65 (MS2/mutU2AF65) and
have been described previously (46). A wild-type U1
snRNA (wtU1) expression plasmid was constructed by
inserting a 600-bp human U1 snRNA gene, including
promoter and termination sequences, into the BamH1 site
of pGem3Z+. All the U1 snRNA expression plasmids
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Figure 1. Inhibitory activity of U1 snRNAs having extended 50ends.
(A) Exogenous 50-end mutated U1 snRNA inhibits the expression of
the targeted Renilla reporter in a dose-dependent manner. HeLa cells
were cotransfected with a Renilla pRL/87mtU1 reporter that contains a
mtU1 binding site at position –87 and variable amounts (1, 2 or 3mg)
of mtU1/+0 plasmid that expresses a 50-end mutated U1 snRNA
designed to base pair to the mtU1-binding site as indicated. ‘+0’ serves
to indicate a normal length 50 end as opposed to an extended 50 end.
As a control, a plasmid expressing wtU1 was used in place of the
mtU1/+0 plasmid. In all cases, a ﬁreﬂy plasmid was also cotransfected
for normalization purposes. The inhibitory activity of the mtU1/+0
plasmid was calculated by dividing the normalized Renilla activity
of the transfection with the pRL/87mtU1+wtU1 plasmids by the
normalized Renilla activity of the transfection with the pRL/87mtU1+
mtU1/+0 plasmids. The wtU1 plasmid did not aﬀect expression of
pRL/87mtU1 and therefore had an inhibitory value set to 1.0. The
standard deviations were calculated from three independent experi-
ments. (B)5 0 end extended U1 snRNAs do not increase inhibitory
activity. The plasmid that expresses mtU1/+0 was used as a parental
vector to construct plasmids that express U1 snRNA extended at
the 50-end +1, +2, +3, +4, +5, +6 and +15nt (mutU1/+1,
mutU1/+2, etc.). These extensions increase the length of the duplex
formed between pRL/87mtU1 pre-mRNA and the mtU1-derived
snRNA. The sequence of the 50 end of the U1 snRNA and the
duplex length is indicated for each case. As described in (A), all
plasmids were transfected along with pRL/87mtU1 and ﬁreﬂy luciferase
and their relative inhibitory activities were calculated. The inhibitory
activities are derived from ﬁve diﬀerent experiments. Standard
deviations are not shown but were <25% in each case. (C)5 0-end
extended snRNAs are stably expressed. A primer extension reaction
was performed with no RNA (lane 1) or with total RNA isolated from
cells transfected with the wtU1 expressing plasmid (lane 2) or the
mtU1-derived plasmids from (B) as indicated (lane 3–10). The 32P-end-
labeled oligo used recognizes both endogenous wtU1 and all mtU1-
derived snRNAs, as indicated to the right of the ﬁgure. The samples
were separated by denaturing PAGE and visualized by autoradiogra-
phy. The product obtained with mtU1/+0 snRNA in lane 3 comigrates
with the product of endogenous U1 snRNA. The product of mtU1/+1
snRNA in lane 4 is diﬃcult to visualize because it would be only 1-nt
longer than the product of endogenous U1 snRNA.
2340 Nucleic Acids Research, 2008, Vol. 36, No. 7had a mutation in stem–loop 3 as previously described
(1,3) that allowed for measuring expression of exogenous
U1 snRNA without detection of endogenous U1 snRNA.
The wtU1 plasmid was used to construct plasmids
expressing 50-end modiﬁed U1 snRNAs such as mtU1/
+0 (Figures 1 and 6), 8bpmtU1 (Figure 6), mtU1/+0/
MS2 (Figure 7) or mtU1 with the indicated extensions in
the 50-end of U1 snRNA (Figure 1). To this end, base
paired oligonucleotides (Sigma) designed to contain the
sequences indicated in Figures 1 and 6, were ligated into
the BglII–BclI site of the wtU1 plasmid. To construct
mtU1/+0/MS2, we used a wtU1 plasmid in which the
stem–loop 1 sequences GGAGATACCATGATCAACG
AAGGTGGTTTTCC of human U1 snRNA were
replaced by an MS2 binding sequence CCTGATACA
CCATCAGGGTTCAGG. All the clones have been
veriﬁed by sequencing in an ABI Prism 310 genetic
analyzer (Applied Biosystems). Plasmid DNA was puriﬁed
with a Maxiprep kit (Qiagen) before transfection.
Luciferase activity measurements
Renilla and ﬁreﬂy luciferase activity was quantiﬁed using
the Dual Luciferase System (Promega) as previously
described (24) in a Berthold Luminometer (Lumat
LB 9507).
Westernblot
The MS2 domain was detected by western blot as
previously described (47) using a 1:2500 dilution of anti-
MS2 antibody kindly provided by Dr Peter G. Stockley
and Gabriella Basnak.
Preparation and analysis ofRNA
Total RNA was puriﬁed using guanidium thiocyanate as
described (25). Primer extensions were done with 6pmol
of ATP g-labeled oligo 50-GCCCTGGGAAAACCACC
TTCG-30 incubated with 0.75mg of total RNA, as
described. These conditions were set up to work in a
linear range. Samples were loaded onto a 14% poly-
acrylamide gel and separated by electrophoresis. Gels were
dried and exposed to a screen that was developed in a
Cyclone phosphorimager (Perkin Elmer).
Invitro binding assay
Electrophoretic mobility shift assay was done as pre-
viously described (18) and contained 32P-labeled RNA,
0.7mM MnCl2, 50mM KCl, 0.1% Triton X-100, 1mg
total yeast tRNA, 20mM Tris–HCl (pH 7.5), 3U RNasin
(Promega), 0.1mM EDTA and 3mg bovine serum
albumin in 15ml. U1 snRNP was added last and the
reaction incubated 5min at room temperature prior to
loading a 6% (60:1) polyacrylamide gel run in Tris–
borate–EDTA buﬀer. Electrophoresis was for 3h at
20V/cm. The puriﬁcation of U1 snRNP from HeLa cells
is described in the Supplementary Data Figure S2.
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Figure 2. Eﬀect of U1-binding site:U1 snRNA duplex length on
inhibition. (A) Shown is a series of Renilla luciferase plasmids with
diﬀerent U1-binding sites cloned at 145nt from the poly(A) signal
(pRL/145/x). Shown in red are nucleotides from the U1-binding site
able to bind endogenous U1 snRNA. The U1-binding site:U1 snRNA
duplex length is indicated for each case. As was done in the
Supplementary Data Figure S1, HeLa cells were transfected with
these plasmids along with a ﬁreﬂy luciferase plasmid for normalization
purposes. Inhibitory activities were calculated as in the Supplementary
Data Figure S1 and the bar graph summarizes ﬁve independent
experiments. The pRL/145mtU1 is the reference control plasmid that
matches pRL/145/+16 except for three point mutations in the U1-
binding site. (B) An electrophoretic mobility shift assay (EMSA) was
used to detect binding of puriﬁed U1 snRNP to 0.03pmol 32P-
radiolabeled RNAs with various types of U1-binding sites. EMSA
conditions were as previously described (18). The RNAs are all
matching except for diﬀerences in the U1-binding site sequence. Lanes
1–9 contain 32P labeled U1-10 RNA that has a 10-nt wt U1-binding
site. Lanes 10 and 11 contain U1-7 RNA that matches U1-10 RNA
except the U1-binding site is 7-nt long. Lanes 12–15 contain U1-8 RNA
that matches U1-10 RNA except the U1-binding site is 8-nt long. The
amounts of puriﬁed U1 snRNP added are indicated (note 100ng U1
snRNP=0.3pmol). The puriﬁcation of U1 snRNP is described in the
Supplementary Data Figure S2. The experiment was repeated  5,
quantitated by phosphorimagery and a Kd of 4 +/  1.5nM was
calculated for the U1 snRNP:U1-10 RNA complex. The U1-8 RNA
bound about 3  weaker than the U1-10 RNA and no detectable
binding to the U1-7 RNA was observed under these conditions.
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U1i isarobust inhibitory mechanism
To systematically analyze parameters that eﬀect U1i
we determined whether inhibition levels would be
inﬂuenced by the amount of transfected plasmid or
time of transfection. To this end, we utilized the dual
luciferase reporter system (Promega) where the pRL/
180wtU1 Renilla luciferase reporter plasmid was targeted
for inhibition by insertion of a 10-nt wild-type U1
snRNA (wtU1) binding site that can base pair endogen-
ous U1 snRNA. A control plasmid (pRL/180mtU1) was
made by insertion of a mutant U1 snRNA (mtU1)
binding site which cannot bind endogenous U1 snRNA.
All Renilla values used in this work were normalized
to a cotransfected ﬁreﬂy luciferase plasmid. The fold
inhibition by U1i is simply the ratio of the normalized
Renilla expression of the mutant plasmid (pRL/
180mtU1) to that of the wild-type plasmid (pRL/
180wtU1). We varied the amount of transfected plasmid
over a 1000-fold range and found that fold inhibition by
U1i remained consistently high (Supplementary Data
Figure S1). Similarly, a time-course experiment showed
that that U1i inhibition was consistently high from 12 to
72h after transfection (Supplementary Data Figure S1).
We also found U1i to give good inhibition when these
constructs were transfected in a variety of other human
cell lines (for example, K562, DU145, HEK, HEK293,
A549, PC3, LnCaP, SK-N-MC, 293F, Jurkat, BHK to
list a few), cell lines from other vertebrates (monkey,
mouse, rat and chicken), as well as from primary
vertebrate cells (data not shown). These results show
that the molecular mechanism that allows inhibition is
robust over a wide range of expression levels of mRNA,
time points and cell types.
5’-endextended U1snRNAs do notgive enhanced inhibition
Next, we wanted to determine whether lengthening the
50-end of U1 snRNA would improve inhibition.
Endogenous U1 snRNA is transcribed in the nucleus,
and then transported to the cytoplasm where Sm proteins
bind, the 30 end is processed and the 50-end is modiﬁed
with a trimethyl-guanosine (TMG) cap (6). Then, U1
snRNA is re-imported into the nucleus and binds the U1
snRNP-speciﬁc proteins to form a mature U1 snRNP.
Others and we have previously shown that U1 snRNAs
with 50-end mutations have a similar maturation and are
capable of gene expression inhibition. This is achieved by
transfection of a wtU1 plasmid that contains the modiﬁed
U1 snRNA sequence under a U1 snRNA promoter and
termination signal. Thus, we expressed a mutant U1
snRNA (called mtU1/+0 snRNA) designed to base pair a
mtU1-binding site inserted 87-nt upstream of the poly(A)
signal in the pRL/87mtU1 plasmid (Figure 1A).
Co-expression of the mtU1/+0 snRNA and the pRL/
87mtU1 Renilla reporter resulted in an inhibition of the
expression of the reporter of up to 20-fold (Figure 1A). As
expected, this inhibition decreased when the amount of the
mtU1/+0 snRNA was decreased (Figure 1A). The 20-fold
level of inhibition is quite respectable as the mtU1/+0 is
expressed at a lower level than endogenous U1 snRNA
in transfected cells, which inhibits at a 30-fold level the
pRL/87wtU1 plasmid that has a wtU1-binding site.
Having established the level of inhibition by mtU1/+0
snRNA, we were now able to determine whether U1
snRNA 50 end extensions would increase inhibition. We
rationalized that the inhibition obtained from these
snRNAs would increase as the base pairing potential to
the target sequence increased. Thus, we constructed a
series of mtU1/+0 plasmids that express mutant U1
snRNAs with the 50 end extended in 1-nt increments
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Figure 3. Analysis of single-point mutations of the U1-binding site. A saturation mutagenesis analysis was performed where all 30 possible single-
point mutations were introduced in the 10-nt wtU1-binding site of the pRL/180wtU1 plasmid shown in the Supplementary Data Figure S1. Each
plasmid was cotransfected with the ﬁreﬂy luciferase control into HeLa cells and inhibitory activities were calculated as described in the
Supplementary Data Figure. S1. The results are plotted in a bars graph where error bars indicate standard deviations of ﬁve independent
experiments. The sequence of the wtU1-binding site and its base pairing with the 11nt of the 50-end of U1 snRNA (blue font) is schematized above
the graph. Each dotted line indicates the mutation (in red font) which is positioned above its corresponding bar graph representing the inhibitory
activity of that mutation. The inhibitory activity of the reporter with a wtU1-binding site is shown in green to the left of the graph. The 6G and 7G
single mutants were combined to give the 6G/7G double mutant whose activity is shown on the far right.
2342 Nucleic Acids Research, 2008, Vol. 36, No. 7(from 1 to 6) or 15nt, which would increase the duplex
formed by the 50-end of U1 snRNA andthe target sequence
from 15 to 31nt (Figure 1B). Unexpectedly, most of the
50 end extendedU1snRNAs werepoorinhibitors andsome
of them had lost inhibitory activity. The same low activity
was obtained with other 50-end extended U1 snRNAs, even
when the length of its base pairing to the target mRNA was
kept constant or when the U1 snRNA extensions ended in
a stem structure to help in stability (data not shown). The
only exception to this pattern was the mtU1/+6 snRNA
that gave an inhibition level similar to the nonextended
mtU1/0 snRNA. Although the basis for the aberrant
activity of mtU1/+6 is not clear, we speculate it may be
due to antisense aﬀects of the extended U1 snRNA rather
than polyadenylation inhibition, as a similar mtU1/+6
construct that only binds 15nt of the target has low
inhibitory activity (data not shown). As shown in
Figure 1C, we conﬁrmed that all the 50 end extended U1
snRNAs were expressed in the cell by primer extension.
Northern blotting and an additional primer extension
assay using an oligo speciﬁc to a sequence tag in stem–loop
3 also demonstrated these U1 snRNAs were expressed at
the same level (data not shown). We also conﬁrmed that
these U1 snRNAs contained the TMG cap by performing
anti-TMG antibody immunoprecipitations and that the
mature forms were localized to the nuclear fraction after
cell fractionation (data not shown). Thus, we conclude
the 50 end extended U1 snRNAs are expressed, but in
general,arepoorinhibitorsascomparedtoanormallength
U1 snRNA.
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Figure 4. Analysis of U1-binding sites with double-point mutations at positions 1 and 2, 1 and 10 or 9 and 10. A saturation mutagenesis analysis was
performed where all possible double mutations were introduced at positions 1 and 2 (A) 1 and 10 (B) and 9 and 10 (C) of the 10-nt wtU1-binding site
of the pRL/180wtU1 plasmid shown in the Supplementary Data Figure S1. The mutations were analyzed and graphed as in Figure 3. The sequence
of the wtU1-binding site and its base pairing with the 11nt of the 50-end of U1 snRNA (blue font) is schematized above the graph. Each pair of
letters indicates a particular mutant where the lowercase red letters correspond to a mutation, while the uppercase black letters match the wtU1-
binding site. Each pair of letters is positioned above its corresponding bar graph representing the inhibitory activity of that mutated U1 site.
Also indicated are the NH values that are deﬁned as the number of continuous hydrogen bonds (see Discussion section). To facilitate comparison
we included the single-point mutations from Figure 2 as red histograms. All double mutants (totals) or double mutants from (A) (1 and 2),
(B) (1 and 10) and (C) (1 and 10) were classiﬁed according to their good, low or no inhibitory activity (>5-, 2–5- and
U 2-fold inhibition,
respectively). Shown is the number of double mutants in each group (D).
Nucleic Acids Research, 2008, Vol. 36, No. 7 2343A10-bpduplex between U1snRNA and its bindingsite
gives nearmaximal inhibition
The previous experiment led us to think that duplex length
may not be an important limiting factor for good
inhibition. To analyze this further, we tested a series of
reporter constructs where the length of the U1-binding site
was changed so as to vary its base pairing potential
to endogenous U1 snRNA. This had the advantage that
all the data are directly comparable as the inhibitor
(endogenous U1 snRNA) is identical for all of the reporter
plasmids. In contrast, expression of a 50-end mutated U1
snRNA has the caveat that some mutations may subtly
aﬀect the inhibitory function of U1 snRNA by eﬀecting
either U1 snRNP maturation or conformation.
As shown in Figure 2, 6 and 7-nt long U1-binding sites
gave no inhibitory activity, whereas an 8-nt long U1-
binding site that could base pair to positions 3 to 10 of
U1 snRNA gave a 6.1-fold inhibition. Later we show that
certain 8-nt long U1-binding sites that base pair to
positions 4–11 or 2–9 of U1 snRNA have no or very
low (<2-fold) inhibitory activity. Thus, not all 8-nt
U1-binding sites are active. Lengthening the U1-binding
site from 8 to 10nt to make a 10-bp duplex further
increased inhibition to 12.8-fold. Lengthening to 11, 12, 14
and 16nt did not give a signiﬁcant increase in inhibition
over that seen with a 10-nt site. Thus, inhibition is
observed with target sites of >8nt and inhibition is near
maximal with a 10-nt site. However, one caveat is the 12,
14 and 16-nt long U1 sites are designed to base pair to nts
12–15 of endogenous U1 snRNA that are already base
paired within stem 1A as part of an intramolecular base
pairing interaction (Supplementary Data Figure S1,
panel A). Thus, modiﬁcations of nts 12–16 of U1
snRNA could aﬀect stem 1A formation and therefore
the activity of U1 snRNP. Therefore, we recommend
target site lengths of 10–11nt.
To determine whether the diﬀerence in activities
between the 7-, 8- and 10-nt long U1-binding sites
reﬂected diﬀerent binding aﬃnities to U1 snRNP, we
performed in vitro binding assays by incubating HeLa cell-
puriﬁed U1 snRNP (Supplementary Data Figure S2 for
puriﬁcation of U1 snRNP) with RNA templates contain-
ing 7-, 8- and 10-nt long U1-binding sites. As shown
in Figure 2B, U1 snRNP is capable of stably binding 8
and 10-nt U1-binding sites but not a 7-nt site. Thus, the
diﬀerences in inhibitory activity in vivo directly correlate
with diﬀerent aﬃnities to U1 snRNP in vitro.
Certain pointmutations in theU1-binding site cause
loss ofinhibition
Previously, we and others showed that a mutated U1-
binding site giving several internal mismatches (1,3) or
even a single central-mismatch (26) in the U1-binding
site:U1 snRNA duplex caused complete loss of inhibitory
activity. However, those studies were limited to just three
mutants. To determine how each target position con-
tributes to inhibition, a saturation point mutagenesis was
performed on the 10-nt U1-binding site. This would also
test whether UU and GU base pairs would be tolerated as
they are known to contribute to RNA:RNA helix stability
in other contexts (27,28). Figure 3 summarizes the analysis
of all 30 possible single-point mutations in the canonical
10-nt wtU1-binding site which were made in an isogenic
plasmid background (pRL/180wtU1, see Supplementary
Data Figure S1) and analyzed by transient transfection.
Inhibitory activities range from 22.3-fold for the wtU1-
binding site to 1.0-fold (no activity) for a U1-binding
site with ﬁve point mutations (Supplementary Data
Figure S1). As an arbitrary cut-oﬀ point, we chose that
any mutant with an inhibitory activity <2-fold would be
considered to have no activity.
The result shows that U1-binding site positions 3–8 are
critical to activity as nearly all point mutations abrogated
inhibitory activity. The only two exceptions are mutant
6G (6-fold inhibition) and mutant 7G (11.5-fold inhibi-
tion) and notably, both would form GU base pairs (GU
pairs) with endogenous U1 snRNA. A double mutant
combining 6G with 7G gave no inhibitory activity,
indicating there is no tolerance for two tandem internal
GU pairs at this position (also shown in Figure 3).
Interestingly, a UU pair at either position gave no
inhibitory activity underscoring the sensitivity of the
duplex to small changes in base pairing potential. Before
proceeding, we point out that these Us in U1 snRNA are
in fact pseudouridines (c). Although it is more accurate to
refer to these as G-c and U-c pairs, prior studies have
shown however that a base pair containing a pseudour-
idine has nearly the same thermal stability and hydrogen-
bonding potential as a base pair with uridine (29,30).
Thus, we will refer to uridines, rather than pseudouridines
at these two positions, a convention also employed by
nearly all U1 snRNA-related publications (31,32).
Given that an 8-nt U1 site retains about 40% activity
of the 10-nt wtU1 site (Figure 2) we were not surprised
that all the single-point mutations in positions 1, 2, 9 and
10 were active (Figure 3). The data follow an interesting
pattern that positions 1, 2, 9 and 10 can be placed in
a hierarchy of 10>1>2>9 where mutating position 10
is most tolerated (most active) and mutating position 9 is
least tolerated (least active). Furthermore, all possible
uninterrupted duplexes of 9bp result in inhibitions
>5-fold (Figure 3). Thus a continuous uninterrupted
helix of 9bp, as opposed to an interrupted 10-bp helix, is
more favorable for inhibition. Similarly to what has been
described earlier, mutations C1U, A2G and A10G, which
would lead to GU pairings, were best tolerated compared
to mutations that disrupt standard Watson–Crick pair-
ings. Also, mutation A2U, which could lead to a UU
pairing, was not tolerated. However, another UU pairing
could be formed in mutation A10U, which resulted in
inhibition similar to the one obtained for the wt U1-
binding site. We cannot exclude that this UU pairing is
not formed and the ﬁrst A of U1 snRNA or another part
of the U1 snRNP complex is interacting with the 10U
mutant. More analysis of the point mutants will be given
in the ‘Discussion’ section. As in Figure 2B, EMSAs were
done on a subset of the single-point mutants to determine
whether their diﬀerences in inhibitory activities reﬂect
diﬀerent binding aﬃnities to puriﬁed U1 snRNP. As
shown in the Supplementary Data Figure S3, the
diﬀerences in inhibitory activity in vivo closely correlate
2344 Nucleic Acids Research, 2008, Vol. 36, No. 7with diﬀerent aﬃnities to U1 snRNP in vitro, indicating
that binding aﬃnity plays a key role in the inhibitory
activity. To determine whether extended base pairing
would increase activity of the partially active mutants
we changed position 11 from G to U so that it could
base pair to the ﬁrst A of U1 snRNA. As shown in the
Supplementary Data Figure S4, we found the G to U
change did not stimulate activity of these partially active
mutants suggesting base pairing to the ﬁrst A of U1
snRNA does not contribute to inhibitory activity. Finally,
before proceeding, we point out it was possible the
mutagenic analysis would inadvertently produce binding
sites either for miRNAs or for proteins that aﬀect mRNA
stability or translation. To rigorously rule this out, we
would have to analyze each point mutation in detail, a
formidable task given the number of mutations. We feel
the likelihood of this happening is low as all constructs
had the same 30UTR. Furthermore, we performed a
bioinformatic analysis that indicated these point muta-
tions do not inadvertently produce new miRNA-binding
sites or binding sites for proteins known to regulate
mRNA (data not shown).
Analysis ofdouble-point mutations
Given that single-point mutations to positions 1, 2, 9 and
10 retained signiﬁcant activity, we proceeded to construct
and analyze a series of double mutations involving these
positions. Twenty-seven double mutants were analyzed,
representing all possible mutations of positions 1 and 2
(Figure 4A), positions 1 and 10 (Figure 4B) and positions
9 and 10 (Figure 4C). As was done in Figure 3, any mutant
with an inhibitory activity <2-fold was considered
inactive. In Figure 4D, we group all 27 double mutants
according to their inhibitory activity, namely good
inhibition (>5), low inhibition (2–5) or no inhibition
(<2). Given the Figure 2 results that an uninterrupted
8-bp duplex had activity, we were surprised that  56%
(15 of 27) of the double mutants lacked inhibitory activity
(<2-fold) (Figure 4D) and this depended on the composi-
tion of the unpaired nucleotides ﬂanking the duplex.
For example, all the C1G/A2n double mutants, where ‘n’
means the second position can be C, G or U, gave no
inhibitory activity (<2-fold) (Figure 4A). However, all the
corresponding C1A/A2n double mutants had inhibitory
activity >4-fold (Figure 4A). We do not know the reason
why a C1G mutation is more destabilizing than a C1A
mutation when located before a mismatch and an 8-nt
long target site. Similarly, all the C1n/A10C or C1n/A10G
double mutants, where ‘n’ is A, G or U, gave very little
inhibitory activity, compared to the C1n/A10U double
mutants (Figure 4B). This correlates with the strong
inhibition observed for the A10U single mutant (Figure 3)
that could reﬂect a noncanonical binding between the U at
position 10 and the U1 snRNP. We also speculate that the
results obtained with position 10 may reﬂect an enhanced
accessibility of this terminus of the duplex as compared to
the other terminus (position 1) that is contiguous with the
rest of the U1 snRNA. Finally, an 8-nt long target site
followed by any double mutant at positions 9 and 10 gave
no inhibition (Figure 4C). This intolerance for mutation of
position 9 is also seen with the single mutant hierarchy
10>1>2>9, where position 9 mutants are the least active
(Figure 3). Inhibitory activities that could reﬂect GU base
pairings were less apparent in the analysis of the double-
point mutations compared to single-point mutations.
The reason may be that GU pairings are less stable
when close to a mismatch or do not help to stabilize an
8-bp long duplex (Figure 4C).
The U1-bindingsite loses inhibitory activity when
partiallymasked by astem
The previous results showing inhibition with certain 8-nt
long target sites as well as targets that would produce a
GU pair, led us to think that U1i could be more
nonspeciﬁc than previously thought. However, the fact
that many 50-end modiﬁed U1 snRNAs are not cytotoxic
even when stably expressed in cells supports the notion
that U1i is speciﬁc (1,3,4). Thus, we considered the
possibility that the natural environment of target
sequences could aﬀect U1i speciﬁcity. In fact, it has been
previously shown that RNA secondary structure inhibits
the splicing activity of a 50ss by occlusion of U1 snRNP
base pairing (10,33). Likewise, we previously showed a
fully active U1-binding site would completely lose activity
when placed within the stem of a 13-bp stem–loop (3).
Importantly, such stem–loop structures had no eﬀect on
reporter plasmid expression in the absence of a U1-
binding site. To further analyze this U1-binding site
occlusion, we systematically and incrementally ‘walked’ a
U1-binding site out of a stem structure in order to
determine when its activity would be restored (Figure 5).
The U1-binding site remained essentially inactive (<2-fold
inhibition) when 0, 3, 6 and 7nt were out of the stem,
indicating U1 snRNP is not very eﬀective at disrupting
stem structures (Figure 5). Inhibitory activity was
observed when eight bases of the U1 site were out of the
stem and activity further increased when 9nt and 13nt
were brought out of the stem. The abrupt gain in activity
at eight bases is consistent with the data in Figures 2–4.
Placement of splicing regulatory sequencesnear a
U1-bindingsite decreases inhibitory activity
There are many examples of splicing enhancer and silencer
sequences binding regulatory proteins that control splicing
by altering 50ss recognition by U1 snRNP (12). To
determine whether such sequences aﬀect poly(A) site
inhibition, we inserted ﬁve diﬀerent regulatory sequences
into a reporter containing a target site for an exogenous
mtU1 (pRL/145mtU1). Sequences A and J have been
described to induce an eﬃcient exon inclusion with several
minigenes tested (17) (Figure 6A). Sequences that bind SR
proteins SF2/ASF or SRp40 were also chosen that induce
eﬃcient exon inclusion or exon skipping, respectively,
when located at a speciﬁc distance upstream of the
U1-binding site (17). Finally, we tested a U-rich sequence
taken from a Fas intron that activates TIA-1-dependent
recognition of the upstream 50ss (14). The sequences
were cloned upstream (A, J, SF2, SRp40) or downstream
(TIA-1) of the mtU1 target site and the spacing and
sequence context of these motifs matched the conﬁguration
Nucleic Acids Research, 2008, Vol. 36, No. 7 2345that is known to aﬀect splicing activity. Control sequences
of the same length were also inserted upstream or
downstream the target site. All plasmids were cotrans-
fected with one of the following U1 snRNA plasmids that
express (i) wtU1 snRNA, which should not form a stable
duplex with the target site, or (ii) mtU1/+0 snRNA
(the same as in Figure 1A) that can form a 10-bp duplex
with the target or (iii) 8bpmtU1 snRNA that can form 8 bp
with the target site (Figure 6B). A ﬁreﬂy luciferase
expressing plasmid was also transfected to normalize
luciferase activity. The results indicate that the presence
of regulatory sequences has no eﬀect on Renilla luciferase
expression per se (Figure 6B, left column). However, when
the mtU1/+0 snRNA is expressed, all the upstream
regulatory sequences decrease inhibition mediated by this
snRNA (Figure 6B, middle column). This result was
expected with the sequences bound by SRp40 but not for
sequences A, J or SF2, which promote exon inclusion and
so would be expected to help recognition of the target site.
The downstream regulatory sequence did not signiﬁcantly
aﬀect inhibitory activity of the U1 snRNA. The eﬀects
were speciﬁc as insertion of control sequences had no
eﬀect. In agreement with what has been shown in Figure 4,
expression of 8bpmtU1, which forms a shorter duplex with
the U1 target site, shows a decreased inhibition compared
to the mtU1/+0 snRNA that can form a 10-bp duplex
(Figure 6B). To determine whether any of the sequences
could help to increase the inhibitory eﬀect observed with a
suboptimal duplex we tested the 8bpmtU1 snRNA that
only forms an 8-bp duplex. Given that TIA-1 has been
described to help U1 snRNP binding to weak 50ss we
expected it could help stabilize the 8bpmtU1 snRNA.
Surprisingly, this was not the case as TIA-1 sequences and
all the other regulatory sequences tested decrease the
inhibition observed with 8bpmtU1.
Analysis ofthe effectof RS domainson the
molecular mechanism ofU1i
The experiments shown in Figure 6 indicate that splicing
factors such as SR proteins decrease silencing eﬃciency
even if they have been described to increase U1 snRNP
binding to a 50ss target sequence. A possible explanation
of this apparent contradiction would be that SR proteins
help U1 snRNP binding by interaction with the RS
domain of U1-70K and, therefore, impede interaction of
U1-70K with other factors essential for U1i mediated
inhibition of polyadenylation. In fact, U1 snRNP inhibi-
tion of papillomavirus late gene expression requires that
the RS domain of U1-70K bind the carboxy-terminus of
poly(A) polymerase (18). A similar molecular mechanism
could be responsible for U1i-mediated inhibition. It has
been previously shown that loop 1 of U1 snRNA, where
U1-70K binds, is required for inhibition (1,4). To test
if the RS domain of U1-70K mediates U1i, we assayed
the inhibition obtained with a modiﬁed U1 snRNP in
which loop 1 has been replaced by an MS2-binding loop
(mutU1/+0/MS2) (Figure 7A). As expected, mutU1/+
0/MS2 by itself does not support inhibition (Figure 7C).
To reconstitute a functional mutU1/+0/MS2, we
co-expressed MS2 alone or fused to the RS domain of
U1-70K (MS2/70K) or the RS domain of U2AF65 (MS2/
U2AF65). Western blotting conﬁrmed expression of the
MS2-derived proteins (Figure 7B). Expression of MS2
fused to the RS domains of U1-70K or U2AF65, but not
MS2 alone, recovered inhibition with mutU1/+0/MS2
(Figure 7C). This demonstrates that not only the RS
domain of U1-70K, but also other RS domains are
involved in U1i. This result agrees with the possibility that
the molecular mechanism that allows U1i would also
require that the RS domain of 70K interacts and inhibits
poly(A) polymerase.
Given that SR proteins help U1 snRNP to bind to 50
splice sites by interaction with the RS domain of U1-70K,
they could impede interaction of the RS domain of U1-
70K with poly(A) polymerase. Support for such a model
comes from the fact that U1-70K’s RS-interacting domain
and its poly(A) polymerase interacting and inhibitory
domain overlap (18,36,46). If the model is true, then we
would expect the RS domain of SR proteins to interfere
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Figure 5. Eﬀect of secondary structure on U1-binding site inhibition.
(A) The pRL/145/stem0 plasmid has a 13-nt wtU1-binding site (the
canonical 10nt are highlighted in yellow) completely occluded in a
stem–loop sequence. The ‘0’ indicates 0nt of the U1-binding site should
be found outside of the stem. As diagrammed, a collection of plasmids
were made and tested that match pRL/145/stem0 except the U1-
binding site increasingly moves out of the stem. The number below
each stem–loop structure indicates the number of U1-binding site
nucleotides that should be found outside of the stem (3, 6, 7, 8, 9
or 13). (B) The plasmids were analyzed and graphed as indicated
in Figure 3. Error bars indicate standard deviations of four diﬀerent
experiments.
2346 Nucleic Acids Research, 2008, Vol. 36, No. 7with silencing. To test this, we tethered speciﬁc RS
domains to the same positions upstream of an active wt
U1-binding site by using an MS2 tethering assay. In the
absence of MS2 protein expression (the ‘no MS2’ bar
graph), the MS2-binding site loops did not eﬀect the
activity of the U1-binding site. Expression of MS2 protein
with no RS domains also had no eﬀect. In contrast,
expression of an MS2 fused with the RS domains of either
U2AF65 of ASF/SF2 disrupted the activity of the U1-
binding site. This disruption is speciﬁc as expression of a
mutated RS domain of U2AF65 and of ASF/SF2 had no
eﬀect. These results indicate that the RS domain of SR
proteins alone is responsible for blocking U1i. To conﬁrm
that these MS2-derived proteins are speciﬁcally binding to
the pre-mRNA substrates in vivo, we made nuclear extract
from UV-crosslinked transfected cells, and did immuno-
precipitation assays (IP)s with an anti-MS2 antibody as
previously described (46). We found the MS2-derived
proteins speciﬁcally associated with pre-mRNAs contain-
ing the wt MS2-binding site as compared to those with a
mutated MS2-binding site (data not shown). Thus, we
conclude tethering of the SR domains of U2AF65 and
ASF/SF2 near to a U1-binding site can disrupt U1i.
DISCUSSION
In this work, we analyze several parameters that aﬀect U1
snRNA-mediated inhibition of gene expression that forms
the basis of U1i. Inhibition is robust as expression of both
abundant and rare mRNAs in diﬀerent cell lines are
strongly repressed (Supplementary Data Figure S1, and
data not shown). In the design of U1i experiments, we
recommend modifying the ﬁrst nucleotides of U1 snRNA
(positions 1–11) and avoiding 50 end extensions of this
sequence (Figure 1 and data not shown). It is unclear to us
why U1 snRNAs with 50-extensions are not capable of
eﬃcient silencing as they contain the expected TMG cap
structure, localize to the nucleus, are bound by Sm
proteins and accumulate in the cell to similar levels as
U1 snRNAs with a regular length 50 end. Interestingly, a
recent report described natural U1-like snRNAs with
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Figure 6. Splicing regulatory sequences interfere with U1 snRNP’s poly(A) site inhibitory activity. (A) Plasmid pRL/145mtU1, whose binding to
endogenous U1 snRNP is schematized at the top of the ﬁgure, served as a parental plasmid to insert speciﬁc sequences upstream or downstream of
the U1 target site, as indicated. Sequences chosen are control sequences (UpX, UpXX or Down X), or sequences A, J, SF2, SR and TIA-1, which
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Nucleic Acids Research, 2008, Vol. 36, No. 7 2347longer 50-ends that are expressed ubiquitously and whose
function has not been described yet (34).
Lessons fornaturally occurring U1-binding sites
Base pairing of U1 snRNA to the target site is essential for
inhibition of the target mRNA. We have studied carefully
the inﬂuence of the length and the eﬀect of mismatches
in the duplex formed by U1 snRNA and the target site.
The results are not only interesting for U1i but are also
important in predicting and understanding U1-binding
sites that naturally occur in the 30 terminal exon of
vertebrate genes. Recently, we used a bioinformatic
analysis followed by experimental veriﬁcation to identify
examples of human genes with U1-binding sites in the 30
terminal exon. A subset of these had the U1-binding site
conserved in the 30 terminal exon of the vertebrate
homolog. We then examined in experimental detail a few
of these human genes with conserved terminal-exon U1-
binding sites and found the U1-binding sites are indeed
active in repressing expression (ref. 45 and Goraczniak,R.
and Gunderson,S.I., unpublished data). The bioinformatic
analysis was based on identifying matches to near-
consensus U1-binding sites, namely MAGGUAAGU
(M = A or C) and NAGGUAAGUA. Thus we excluded
any hits that had an internal mismatch. However, given
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of various MS2 fusion proteins. mutU1/+0/MS2 is identical to U1 snRNP shown in the Supplementary Data Figure S1A but loop 1 has been
replaced by an MS2-binding sequence and the 50-end binds a mutated sequence in the 30 terminal exon of the Renilla reporter plasmid as shown.
(B) Analysis of the expression of MS2 fusion proteins. HeLa cells were transfected with the plasmids that express a control protein, MS2 alone or
MS2 fused to the RS region of U1-70K (MS2/70K) or the RS region of U2AF65 (MS2/U2AF65) and extracts were collected at 48h posttransfection.
MS2 expression was evaluated in the extracts by western blot analysis. (C) Reconstitution of functional U1i complexes by tethering RS domains to
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described (46). Western blotting was used to conﬁrm that the MS2 fusion proteins were expressed to a similar level (data not shown).
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bioinformatic analysis will have to be expanded to include
6U and 7U which will undoubtedly turn up additional
genes with conserved U1-binding sites. Furthermore, such
future bioinformatic analysis will also scan for potential
secondary structure that is suﬃcient to strongly impair
activity (Figure 5). Indeed, one of the genes we studied in
experimental detail (45) has its U1-binding site trapped
within a phylogenetically conserved base pairing interac-
tion that base pairs to 5 of 10nt of the U1-binding site,
just suﬃcient, as per Figure 5, to inhibit its activity.
Through mutational and compensatory mutational
analysis, we demonstrated this base pairing impairs
the inhibitory activity of the U1-binding site. Given the
diﬃculty of prediction of secondary structure, the
bioinformatic analysis of such base pairing will be a
challenge that we have to meet for future studies.
Lessons for hydrogen bonding between U1 snRNP
and the 5’ss
The results of the mutagenesis are also of interest to
understand the role of hydrogen bonding in the U1
snRNP-50ss interaction used during splicing and alter-
native splicing. There is strong genetic and biochemical
evidence that U1 snRNA base pairing to 50ss is critical for
50ss selection (7–9). However, there are other factors that
contribute to 50ss choice. For example, SR proteins along
with some of the U1 snRNP proteins aﬀect base pairing of
U1 snRNA to the 50ss (35–37). It has been shown that
yeast U1C can bind a consensus 50ss and so it could assist
in splice site choice and base pairing of U1 snRNA (35).
However, this has only been demonstrated in yeast, where
50ss sequences are generally consensus and U1 snRNP is
more complex than in higher eukaryotes. Also, U5 and U6
snRNPs base pair to the 50ss and may be preassembled to
U1 snRNP before U1 snRNP binding to the 50ss (38).
In spite of this, competition experiments clearly showed
that the stability of the duplex formed by U1 snRNA and
the 50ss governs the choice between nearby 50ss (32). Our
results also agree with a strong inﬂuence of U1 snRNA
binding in 50ss choice. We believe that the saturation
mutagenesis analysis performed in this work allows a good
and quantitative method to evaluate cellular U1 snRNA
binding to a 50ss without the confounding aﬀects of U5 or
U6 snRNA or other components of the spliceosome. The
results reveal that positions 3 to 8 [GGU(A/G)(A/G)G]
are critical, but are not suﬃcient to allow inhibition
(Figures 2 and 3). A similar [GGU(A/G)AG] sequence can
be found in the Shapiro and Senapathy (39) consensus
matrix [(A/C)AGGU(A/G)AGUn], which shows the
conservation observed after the alignment of 1446 50ss
sequences. As this matrix should reﬂect the eﬀect in a 50ss
of several splicing factors, including U5 and U6 snRNPs,
we propose that the low conservation of a G at position 7
is not forced by U1 snRNA binding. Similarly, A/G is
favored at position 2 in our results whereas it is A in the
matrix because splicing requires an interaction between
this A and a U from U5 snRNP (40). Nucleotides
surrounding the position 3 to 8nt core seem less critical
for U1 snRNA binding. Point mutations are mildly
tolerated at position 9, but eﬃcient splicing requires a U
to base pair with A from U6 snRNP and this is reﬂected
in the Shapiro and Senapathy consensus matrix.
Surprisingly, A or U at position 10 resulted in almost
the same level of inhibition, suggesting a similar eﬃciency
of UA or UU base pairing, which is not detected in the
rest of the duplex. We cannot exclude that the ﬁrst A of
U1 snRNA or another part of the U1 snRNP complex
may interact with the 10U mutant. The fact that the
Shapiro and Senapathy matrix does not reﬂect any
preference for position 10 indicates either that A or U
nucleotides are detrimental to other factors or that when
U1 snRNA binding to the 50ss is too stable, splicing is less
eﬃcient due to a delayed release of U1 snRNP from the
spliceosome (40,41).
Noncanonical UU pairings have been described in 50ss
from yeast and human at positions 6 and 7 whereas we
ﬁnd UU pairings are not allowed. Instead, we observe
inhibitory activity only with UA standard Watson–Crick
base pairings and GU wobble base pairs, both of which
contribute to 50ss selection (32). GU wobble pairs could
not only be formed at positions 6 and 7, but also at 1, 2
and 10 (Figure 3). Structural and biochemical studies with
model RNA oligonucleotides conclude that a single GU
pair within an A helix induces only minor changes in
thermodynamic stability consistent with a 2-hydrogen
bond pattern of similar but slightly less strength to that of
an AU pair. However, the inhibition we observe with all
GU containing duplexes is relatively low compared to the
wt sequence. This is particularly striking at position 2
where a GU wobble shows reduced activity comparable
to a CU and UU mismatch. Also, tandem GU pairs
may allow splicing even if they could lead to changes
in thermodynamic stability consistent with loss of the
2-hydrogen bond pattern (32,42,43). However, tandem
GU wobbles at position 6 and 7 completely abrogate
inhibition. The decreased inhibition observed for duplexes
with terminal wobbles (positions 1 and 10) is consistent
with reports that terminal GU pairs are more unstable
than internal GU pairs due to lack of base stacking at the
loop side, i.e. the side away from the helix. Importantly, a
terminal 50GU does not equal a terminal 50UG in that
50GU is much more thermodynamically stable because of
diﬀerences in stacking, a phenomena known as the ‘50-end
rule’ (42,44). Both the position 1U and 10G single U1 site
mutants produce a terminal 50U-G pair, the less stable
category, a fact consistent with their lowered activity
relative to the wtU1 site. As for the signiﬁcant reduction in
activity observed with wobbles at positions 2, 6 and 7 we
consider it possible that U1 snRNP proteins can sense a
loss in the smooth geometry arising from continuous
Watson–Crick pairs. Resolution of these outstanding
issues will require a concerted eﬀort involving structural
and biochemical approaches.
Models basedon "G andNH
Our analysis of the duplex formed by the U1 snRNP and
the target site indicates that higher inhibition is obtained
with duplex lengths of 10–16nt (Figure 2). For shorter
duplexes we ﬁnd some 8-bp continuous duplexes inhibit
Nucleic Acids Research, 2008, Vol. 36, No. 7 2349while other 8-bp duplexes do not (Figures 2 and 4).
Furthermore, the activities of some of the point mutations
in Figure 3 were unexpected. In order to develop a model
to explain these diﬀerences, we took advantage of two
recent reports that analyzed an extensive series of point
mutations to the canonical 50ss for changes in splicing
eﬃciency (31,32). Interestingly, both reports proposed
distinctly diﬀerent models to explain the behavior of the
50ss mutants. In the ﬁrst case, a model based on free
energy (G) calculations of the various U1 snRNA:50ss
duplexes was found to be a good predictor of splicing
activity of the 50ss mutants (32). Thus, an increase in G
of the U1 snRNA:50ss duplex correlated well with an
increase in splicing activity. We applied the G model to
our mutational analysis of the U1 snRNA:U1 site duplex
and found a good correlation with inhibitory activity.
However, we also found many exceptions where the
correlation broke down, especially for those mutants
producing a GU pair that greatly reduced the value of this
approach (Gunderson,S.I., unpublished data). Given these
exceptions we examined a second published model based
on counting the number of continuous hydrogen bonds
(NH) in an uninterrupted U1 snRNA:50ss duplex (31).
When NH>14, this model predicts that the sequence
should be active in pre-mRNA splicing. When the helix
had mismatches, then NH>15 was necessary for activity
with >5 hydrogen bonds occurring 30 to the mismatch and
>6 hydrogen bonds 50 to the mismatch. Notably, this
analysis counted GU wobble pairs (but not UU pairs) as 2
hydrogen bonds. In applying this hydrogen bond model to
our data, we not only found some correlation but also
many inconsistencies. By making modiﬁcations of the
model, in particular when terminal GU pairs were
excluded in the calculation of the NH value, we found a
signiﬁcant improvement in its predictive value. Thus, we
observe no activity (<2-fold) for all U1 sites with NH<18
and good activity (consistently >5-fold) for all U1 sites
with NH>21 (see NH values in Figure 4). The model does
not do well, however for U1 sites where NH=19 or
NH=20 as many sites are inactive whereas others are
active (up to 6.8-fold). We tried additional ad hoc
modiﬁcations to the model but in each case there was
little or no improvement. Furthermore, none of the
models explain the lowered activity pattern of the 6G
and 7G single mutants that make an internal GU pair (see
above). Finally, as with any mutational analysis, we
cannot formally rule out that a given mutation creates a
binding site for a factor that competes with U1 snRNA.
Specificity of U1i
U1 snRNP-mediated inhibition can be detected with some
targets of only 8nt. Thus, U1i could have oﬀ-target
inhibition levels as seen with RNAi, where 6-nt long
targets may function for inhibition. Our results indicate
that a 50-end modiﬁed U1 snRNA designed to bind a 10-nt
long target, could also interact with sequences with
mismatches at the end of the duplex and could also
form some GU base pairs. We ﬁrst thought that binding
to mismatches could be driven by high levels of
endogenous U1 snRNA (typically 1 million/cell) as this
is what was evaluated in the experiments shown in
Figures 2–5. However, transfection of a plasmid that
expresses a 50-end mutated U1 snRNA also induces
inhibition of the expression of a reporter gene with a
target of 8nt (Figure 6B). We have not yet evaluated
whether GU base pairing allows functional inhibition to
exogenous U1 snRNAs.
So what are the points in favor of U1i speciﬁcity? First,
U1i only works in the 30 terminal exon (1,2). Second,
similar to what has been described for U1 snRNA
function in splicing (10,33), secondary structures occlude
target sequences (Figure 5). Our detailed study of the
eﬀect of stem structures concludes that the complete target
sequence, that is at least 8nt, should be accessible to U1
snRNP. Thus, speciﬁcity could be greatly enhanced by this
fact, as binding sites for U1i must be in the terminal exon
of target genes, which are generally enriched in secondary
structures. Surprisingly, speciﬁcity may also be enhanced
because factors that help U1 snRNA binding to a target
for splicing actually decrease U1 snRNP-mediated inhibi-
tion (Figure 6B).
TIA-1 has been described to increase U1 snRNA
binding to weak 50ss (14). Thus, we rationalized that
TIA-1 could help binding of 50-end mutated U1 snRNAs
to sequences that lack perfect complementarity and
therefore increase oﬀ-target inhibition of U1i. This is
important as putative TIA-1-binding sites have been
found in the 30UTR of almost 3% of the genes analyzed,
where TIA-1 could function to control mRNA translation
(48). Thus, we analyzed the eﬀect on U1i of TIA-1-binding
sequences located downstream of a target site in the
presence of 50-end mutated U1 snRNAs that lack perfect
complementarity to the target (Figure 6B). Opposite to
what we expected, TIA-1-binding sequences abolished U1i
when the target had an eight out of 10 complementarity
to U1 snRNA (Figure 6B). However, TIA-1 sequences
did not aﬀect inhibition of a U1 snRNA with perfect
complementarity to the target. This surprising result
allows us to suggest that there is a TIA-1-mediated
mechanism that increases the speciﬁcity of U1i. It will be
of interest to determine the molecular mechanisms that
allow this eﬀect.
SR proteins bound close to target sequences can also
interfere with U1i. Several molecular mechanisms may
explain this result. The RS domain of SR proteins has
intrinsic aﬃnity for double-stranded RNA regions and
can promote U snRNA- pre-mRNA pairing (49). Thus,
SR proteins bound close to target sequences could
facilitate binding of U1 snRNP in a conformation which
is not optimal for mediating U1i eﬀects. We also
hypothesized that as SR proteins help U1 snRNP base
pairing to the RNA by binding of their RS domain with
the RS domain of U1-70K, this could impede interaction
of U1-70K with other factors that could be essential for
U1i. In agreement with these hypotheses, we show that the
RS domain of SR proteins decreases U1i eﬃciency
(Figure 7E). Also, we show that the RS domain of U1-
70K is required for U1i (Figure 7C), probably as U1i
needs binding of the RS domain of U1-70K to the
carboxyl-terminus of poly(A) polymerase, as required
for U1 snRNP inhibition of papillomavirus expression.
2350 Nucleic Acids Research, 2008, Vol. 36, No. 7Thus, SR proteins could drive U1 snRNP functionality in
a way that a given U1 snRNA:target site complex could
only induce commitment to splicing, in the presence of SR
proteins, or inhibit polyadenylation, in the absence of SR
proteins. U2AF65 RS eﬀects on U1i seem especially
complex. Functional U1i is observed when the RS domain
of U1-70K is substituted by the RS domain of U2AF65
(Figure 7C) or when this is tethered upstream of a
polyadenylation signal (46), while the same RS domain of
U2AF65 is able to inhibit U1i when tethered upstream
of a target sequence (Figure 7B). Binding of U1 snRNA
to the terminal exon should normally induce U1i as
few examples exist of pre-mRNA 30UTRs that bind SR
proteins.
The conclusions obtained in this work help us to make
some recommendations for eﬀective U1i. As has been
previously determined, target sequences should be located
in the 30terminal exon of target genes. Secondary
structures should be avoided as well as sequences bound
by SR proteins. Target sequences should be avoided that
have U-rich sequences downstream. The target should
bind nucleotides 1 to 11 or 2 to 11 of the 50-end modiﬁed
U1 snRNA. We do not recommend longer sequences as
they may force the opening of the ﬁrst stem of U1 snRNA
and they may have a higher risk of oﬀ target inhibition.
We also recommend avoiding internal G and U nucleo-
tides, as they allow GU wobbles that carry the risk of
lowering the speciﬁcity. We believe that these recommen-
dations should govern the design of U1i experiments.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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